Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > The study was done with INHALED Nitric Oxide NOT R107

<< Previous

Bullboard Posts

Next >>

Comment by Bigginvestoron Jul 26, 2021 4:19pm

128 Views

Post# 33605674

RE:The study was done with INHALED Nitric Oxide NOT R107

losingmyshirt wrote:
Good ole Bob trying his best to deserve his big salary by releasing fluffy news items such as he did today.

The smarter ones amongst you would have seen through the latest news immediately.
It has ABSOLUTELY NOTHING to do with R107 which is Kalytera's latest flavour.

GO KALYTERA.
GO SALZMAN

read the news release again it clearly says r107 .

<< Previous

Bullboard Posts

Next >>

AI companies to invest in